Latest News and Press Releases

YIV-906, in combination with sorafenib, shows promising Phase 2b results for advanced liver cancer, enhancing efficacy and reducing toxicity.

Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for...

Dublin, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market by Devices & Consumables (RF, Microwave, Cryoablation. Embolization), Procedures (Thermal Ablation, Non-Thermal...

Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment for uHCCFinal analysis...

A post hoc analysis found the efficacy of camrelizumab plus rivoceranib was superior to sorafenib regardless of baseline liver function as measured by both albumin-bilirubin grade and Child-Pugh...

FORT LEE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...

PRINCETON, N.J. and FORT LEE, N.J. Oct. 17, 2023 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma), one of China’s largest pharmaceutical companies based on market...

FORT LEE, N.J. and PRINCETON, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated...

Washington, DC, Oct. 01, 2023 (GLOBE NEWSWIRE) -- Today marks the start of Liver Cancer Awareness Month, which will feature the monthlong #OctoberIs4Livers multifaceted campaign led by Global Liver...

New York, USA, June 26, 2023 (GLOBE NEWSWIRE) -- Hepatocellular Carcinoma Clinical Trial Analysis: DelveInsight Evaluates a Robust Pipeline as 90+ Influential Pharma Players to Set Foot in the...